Restless Legs Syndrome

New Guidelines Published on Opioid Use in Refractory RLS Treatment

By January 09, 2018

Although the research found opioid use to have a favorable risk-benefit ratio, other avenues of treatment should be considered before opioid prescription including addressing iron stores and combination therapy.

Antihistamine Overdose in Patient with Insomnia and RLS

By June 13, 2017

In this case, a 57-year-old Caucasian woman presented with hypersomnolence and altered mental status after having ingested 20-30 diphenhydramine 25mg tablets.

Risk of Death Up with Long-Term Quinine Exposure

May 15, 2017

Increased risk of death more pronounced among those younger than 50 years regardless of indication

Drug-Free Therapy for RLS Available in Pharmacies

By November 08, 2016

Medi USA announced the availability of the restiffic compressive foot wrap for the treatment of restless legs syndrome (RLS).

Requip Labeling Updated with New Warnings, Dosing Information

By September 13, 2016

The Food and Drug Administration (FDA) has approved labeling updates regarding dosage and warnings for Requip (ropinirole; GlaxoSmithKline) tablets.

Are Opioids Effective for Restless Legs Syndrome?

By June 30, 2016

Opioids appeared to be efficacious for treating symptoms of restless leg syndrome (RLS) but there is no definitive evidence regarding the issue of safety, a study published in Cochrane Database of Systematic Reviews concluded.

New Drug-Free Option for RLS Launched

By June 09, 2016

Medi USA announced the launch of restiffic compressive foot wrap, a new drug-free option for patients with restless legs syndrome (RLS).

Treatment Significantly Improves Symptoms in Severe RLS

By May 24, 2016

For patients with severe restless legs syndrome (RLS), gabapentin enacarbil (GEn) was shown to significantly improve RLS symptoms and the consequences of these symptoms.

Pregabalin Demonstrates Efficacy in Restless Legs Syndrome

By May 19, 2016

Pregabalin may help improve symptoms of restless legs syndrome (RLS) and decrease sleep disturbances, according to a recent study in Annals of Pharmacotherapy.

Gabapentin Enacarbil May Improve Quality of Life in RLS

By May 18, 2016

A recent study published in CNS Drugs concluded that gabapentin enacarbil (GEn) taken once daily significantly improved quality of life in adults with moderate-to-severe primary restless legs syndrome (RLS) across all study time points.

Gabapentin Enacarbil Evaluated in Patients with Pain Linked to RLS

By May 13, 2016

Gabapentin enacarbil (GEn) taken once daily, was shown to significantly improve pain associated with moderate-to-severe restless legs syndrome (RLS) in adults, when compared to placebo.

RLS Common in Ankylosing Spondylitis Patients

April 10, 2015

Peripheral arthritis, uveitis, anemia, smoking, polyneuropathy higher in AS patients with RLS

First Device for RLS-Disrupted Sleep Approved

May 29, 2014

Sensory Medical announced that the FDA has granted commercial clearance for Relaxis, the first nonpharmacological medical device to improve the quality of sleep in patients with primary Restless Legs Syndrome (RLS).

Pregabalin Treatment Effective in Restless Legs Syndrome

February 13, 2014

For patients with restless legs syndrome (RLS), pregabalin treatment is associated with improved treatment outcomes versus placebo and with lower augmentation than that seen with 0.5mg pramipexole.

Is Roseroot a Reliable Alternative for Nervous System Ailments?

November 20, 2013

The perennial plant has been used to treat depression, muscle weakness and muscle fatigue.

Drug Therapies for Restless Legs Syndrome

June 24, 2013

Willis-Ekbom disease, otherwise known as restless legs syndrome, is a neurologic disorder that affects up to 10% of Americans. Individuals with RLS develop irresistible urges to move their legs accompanied by unusual or unpleasant sensations in the legs.

Restless Leg Syndrome Linked to Higher Mortality in Men

June 13, 2013

Men with restless legs syndrome (RLS) have a significantly increased risk of mortality, independent of other known risk factors.

Horizant ER 600mg Returning to Shelves

May 20, 2013

Shipments of Horizant ER tablets have commenced, and are expected to be available to patients in the first week of June.

Treating Sleep Disorders in the Geriatric Population

April 24, 2013

As the U.S. population ages, clinicians can expect more geriatric patients seeking evaluation and treatment for sleep disorders.

FDA Announces Horizant 600mg Tablet Shortage

April 17, 2013

GlaxoSmithKline is currently experiencing a shortage of Horizant 600mg extended-release tablets, according to the FDA. Horizant is a prodrug of gabapentin that is indicated for postherpetic neuralgia and for moderate-to-severe primary restless legs syndrome in adults.

Two Drug Classes Found Effective for Restless Legs Syndrome

March 06, 2013

In patients with restless legs syndrome, dopamine agonists and calcium channel alpha-2-delta ligands are effective in reducing symptoms and improving sleep and quality of life, although adverse events are common and often lead to treatment withdrawals.

SAFETY ALERT: Possible Heart Failure Risk with Mirapex

September 19, 2012

The FDA notified healthcare professionals about a possible increased risk of heart failure with Mirapex (pramipexole tablets; Boehringer Ingelheim).

Neupro Now Available for Parkinson's and Restless Leg Syndrome

July 16, 2012

UCB announced that Neupro (rotigotine transdermal system) is now available as a once-daily patch for the treatment of signs and symptoms of early and advanced stage idiopathic Parkinson's disease (PD) and moderate-to-severe primary restless legs syndrome (RLS).

Neupro Approved for Parkinson's and Restless Legs Syndrome

April 03, 2012

UCB announced that the FDA has approved Neupro (rotigotine transdermal system) for the treatment of the signs and symptoms of advanced stage idiopathic Parkinson's disease (PD) and as a treatment for moderate-to-severe primary restless legs syndrome (RLS).

Phase 3 Study of Lyrica for Restless Legs Syndrome

December 16, 2011

Pfizer announced results from its Phase 3 study of Lyrica (pregabalin) for the treatment of restless leg syndrome (RLS).

Horizant Approved for Restless Legs Syndrome

April 08, 2011

GlaxoSmithKline and XenoPort announced that the FDA has approved Horizant (gabapentin enacarbil extended-release tablets) for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) in adults.